AI assistant
Sending…
Propanc Biopharma, Inc. — Director's Dealing 2021
Aug 20, 2021
34906_dirs_2021-08-20_0eb81e36-d4d8-4251-b6be-639e68aa66d9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Propanc Biopharma, Inc. (PPCB)
CIK: 0001517681
Period of Report: 2021-08-17
Reporting Person: Nathanielsz James Andrew (Director, CEO/CFO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-08-17 | Common stock, par value $0.001 | A | 5928000 | — | Acquired | 5928004 | Indirect |
| 2021-08-17 | Common stock, par value $0.001 | A | 2800000 | — | Acquired | 2800000 | Indirect |
More from Propanc Biopharma, Inc.
Interim / Quarterly Report
2026
May 14
Capital/Financing Update
2026
Apr 10
Proxy Solicitation & Information Statement
2026
Mar 19
Board/Management Information
2026
Feb 26
Interim / Quarterly Report
2026
Feb 17
Capital/Financing Update
2026
Feb 2
Delisting Announcement
2026
Jan 7
Capital/Financing Update
2025
Dec 30
Proxy Solicitation & Information Statement
2025
Dec 29
Declaration of Voting Results & Voting Rights Announcements
2025
Dec 10